Abstract
Background
In recent years, less options are available for treating carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant Pseudomonas aeruginosa. The present study investigatesthe susceptibility rates to imipenem/relebactamfor the treatment of intra-abdominal infections (IAIs), respiratory tract infections (RTIs) and urinary tract infections (UTIs) caused by A. baumannii and P. aeruginosain China.
Methods
1,886 P. aeruginosa and 1,889 A.baumanniiisolates were collected in 21 centers (7 regions) as part of the global SMART surveillance program between 2015 and 2018. Antimicrobial susceptibility testing was performed according tothe Clinical and Laboratory Standards Institute (CLSI) recommendations using the broth microdilution methodology in the Peking Union Medical College Hospital.
Results
Rates of imipenem-non-susceptibilities of P. aeruginosa and A. baumanniiisolates were 44.3% and 79.0%, whereas the multidrug-resistance (MDR) rateswere 44.3% and 81.9%, respectively.For P. aeruginosa, susceptibility rates to imipenem/relebactamwere 84.2% at aCLSI breakpoint of ≤ 2 mg/L compared to 55.7% for imipenem. The MIC90 of imipenem/relebactam(8 mg/L) was one fourth of that of imipenem (32 mg/L).The susceptibilities of imipenem-non-susceptible and MDRP.aeruginosastrains were similarly restored by imipenem/relebactam in non-ICU and ICU wards.The susceptiblity rate of A. baumannii isolates to imipenem was 21.0% and to imipenem/relebactam 22.2%.
Conclusions
Imipenem/relebactam provides a therapy option for infections caused by MDRor imipenem-non-susceptible P. aeruginosa infections in China.
Antimicrobial susceptibility of bacteria causing urinary tract infections in Latin American hospitals: results from the SENTRY Antimicrobial Surveillance Program (1997)